Search

Your search keyword '"Deckelbaum, Lawrence I."' showing total 148 results

Search Constraints

Start Over You searched for: Author "Deckelbaum, Lawrence I." Remove constraint Author: "Deckelbaum, Lawrence I."
148 results on '"Deckelbaum, Lawrence I."'

Search Results

1. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI

3. Supplemental Material, sj-docx-1-cpt-10.1177_10742484221121507 - CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

4. Early and late recurrent cardiovascular events among high‐risk patients with an acute coronary syndrome: Meta‐analysis of phase III studies and implications on trial design

5. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial

7. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction

8. Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction†

15. Validation of continuous radionuclide left ventricular functioning monitoring in detecting silent myocardial ischemia during balloon angioplasty of the left anterior descending coronary artery

19. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction

20. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A‐I [Human]) to Enhance Cholesterol Efflux Capacity.

21. Developing New Treatments for Heart Failure

22. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction.

23. Tirofiban (Aggrastat®)

25. Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy)11The principal investigators of the RESTORE (Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis) trial and their associations are listed in the appendix of The RESTORE Investigators.6

27. Intracoronary Doppler Assessment of Moderate Coronary Artery Disease

41. Near-IR FT Raman spectroscopy of human aorta

Catalog

Books, media, physical & digital resources